Evidence Hub

Exploring the therapeutic potential of Beta-3 adrenergic agonists in overactive bladder: A comparative analysis of monotherapy versus combination therapy strategies

Bushra A. Lafta, Jawad K. Hasan, Safaa A. Mohssin, Firas S. Attar, S. Abbas, Noor A. Abdullah

Wiadomosci lekarskie, 2026

400 participants

Abstract

OBJECTIVE

Aim: to compare effects and side-effect profiles between mirabegron monotherapy and 2 combination treatments including mirabegron in patients with OAB.

PATIENTS AND METHODS

Materials and Methods: Study is nonrandomized, prospective, and observational; conducted in 22 centers, 400 patients with OAB symptoms. Patients administered 50 mg monotherapy of mirabegron for 8 weeks. Responders received monotherapy (Group 0, n=109) and non-responders allocated to double therapy with mirabegron plus Solifenacin 5mg (Group 1, n=145) or mirabegron plus Flavoxate/Uripas (Group 2, n=146) for an additional eight weeks. Providing bladder volume, postvoid residual and BWT served as primary end points.

RESULTS

Results: Prevalence of urgency, frequency, and nocturia was high in cohort (92.8%, 88.5%, and 76.5%), but that of UUI35 was low at 9%. This indicates that patients are clearly of OAB-dry phenotype. Mixed storage-voiding symptom was most frequent among 53.8%. An unusual baseline comparison population along to chew, - 200% male and severe symptom' GROUPS 2 BWT a benefit of mirabegron\+\-Solifenacin); one could get; other couldn't (-36ml vs. -31ml). End-point analysis did not allow exclusion of therapeutic equipoise of REGULAR vs. DROP for final PVR (between-group difference: -1.48 mL, p = 0.065).

CONCLUSION

Conclusions: Beta-3 agonist as monotherapy is a potent, multimodality first-line therapy with strong influence of severe disease. Each of combinatory treatments show…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 400 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free